Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Terminated 4Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × ostarine × Clear all
NCT01616758 2024-03-08

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

GTx

Phase 2 Terminated
22 enrolled 5 charts
Breast

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Veru Inc.

Phase 3 Terminated
5 enrolled
Breast

Breast Neoplasms

NCT04869943 2024-01-26

ARTEST

Veru Inc.

Phase 3 Terminated
52 enrolled
Breast

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02368691 2020-11-18

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

GTx

Phase 2 Terminated
32 enrolled 12 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡